Epidemiological survey of haemophiliacs with inhibitors in France: Orthopaedic status, quality of life and cost - The 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 1, 2009, Pages 4-11

  Stieltjes, Natalie ^a   Torchet, Marie F ^b   Misrahi, Laure ^c   Roussel Robert, Valérie ^a   Lambert, Thierry ^d   Guérois, Claude ^e   Bertrand, Marie A ^f   Briquel, Marie E ^g   Borel Derlon, Annie ^h   Dirat, Gérard ⁱ  

^a Hôpital Cochin ^*  (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CRESGE   (France)

^d BICÊTRE HOSPITAL   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g CHU NANCY BRABOIS   (France)

^h CHU CÔTE DE NACRE   (France)

ⁱ Unite de Reeducation Fonctionnelle Specialisee dans i'Hémophilie La Perle Cerdanne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEMOPHILIA; HUMAN; MALE; ORTHOPEDICS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FACTOR IX; FACTOR VIII; FEMALE; FRANCE; HEALTH CARE COSTS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58849145534     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328313fc8e     Document Type: Article

References (31)

1. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232:25-32.
2. van den Berg HM, Fischer K. Prophylaxis for severe hemophilia: experience from Europe and the United States. Semin Thromb Hemost 2003; 29: 49-54.
3. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104:3494-3500.
4. Carcao MD, Aledort L Prophylactic factor replacement in hemophilia. Blood Rev 2004; 18:101-113.
5. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9:418-435.
6. Lusher JM. Management of patients with factor VIII inhibitors. Transfus Med Rev 1987; 1:123-130.
7. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor Vlla. Blood Coagul Fibrinolysis 1998; 9:119-128.
8. Hedner U. Recombinant coagulation factor Vila: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26:363-366.
9. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3 Suppl 2):3-6.
10. Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70:565-570.
11. Ware JE. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven; 1996.
12. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-233.
13. Brooks R, Rabin R, de Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective - Evidence from the EuroQol BIOMED Research Program. The Netherlands: Kluwer; p. 299.
14. Jasso-Mosqueda JG, Omnes L-F, Chicoye A, Durand-Zaleski I. Medico-economic assessment in the early third millennium. Hé matologic 2001; 7:445-452.
15. Jasso-Mosqueda JG. 15 Description of the management of severe haemophilia A with the computerized patient's information programme: interests and limits. J d'economie Méd 2000; 6:323-330.
16. Sultan Y. Prevalence of inhibitors In a population of 3435 hemophilia patients in France. French hemophilia study group. Thromb Haemost 1992; 67:600-602.
17. Fressinaud E, Dieval J, Gay V, Guérin V, Lambert T, Donadieu J., for the FranceCoag Network FranceCoag Network: a national multicenter prospective cohort for congenital bleeding disorders. In: Proceedings of the 47th Annual Meeting of the American Society of Hematology, Atlanta; 2005.
18. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group, secretariat. Haemophilia 2000; 6:23-32.
19. Aznar JA, Magall6n M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6:170-176.
20. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group. Blood 2003; 102:2358-2363.
21. Fischer K, Bom JG, Mauser-Bunschoten EP, Roosendaal G, Berg HM. Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia 2005; 11:43-48.
22. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12:154-162.
23. Rodriguez-Merchan EC, Rocino A, Ewenstein B, Bartha L, Batorova A, Goudemand J, et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 2004; 10 (Suppl 2):50-52.
24. Goddard N. Case studies; orthopaedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia 2005; 11 (Suppl 1):32-37.
25. Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5:397-401.
26. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9:521 -540.
27. Auerswald G, von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10:499-508.
28. Mariani G, Scheibel E, Nogao T, Kasper CK, Ewing NP, Mauser-Bunschoten E, et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31 (2 Suppl 4):62-64.
29. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86:983-988.
30. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (Suppl 3):25-32.
31. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor Vila in haemophilia patients with inhibitors. Haemophilia 2005; 11:203-207.